Asset
PEMBROLIZUMAB
TuHURA Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06940440 | phase1 | recruiting | 2025-10-01 | 2026-05-31 | TuHURA Biosciences, Inc. | IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) |
| NCT06947928 | phase2_3 | recruiting | 2025-12-11 | 2027-03-31 | TuHURA Biosciences, Inc. | Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma |
FDA applications (0)
This company has no applications containing this asset.